Variables | Univariate | Multivariate | ||
Hazard Ratio (95% CI) p-value | Hazard Ratio (95% CI) p-value | |||
Age ≥ 65 y (vs. <65 y) | 3.162 (2.152 < 4.644) | <0.001 | 2.611 (1.739 < 3.920) | <0.001 |
Male gender (Y/N) | 1.230 (0.880 < 1.718) | 0.226 |
|
|
MPO-ANCA (vs. PR3-ANCA) | 0.899 (0.517 < 1.562) | 0.705 |
|
|
General manifestation (Y/N) | 1.002 (0.701 < 1.430) | 0.993 |
|
|
ENT involvement (Y/N) | 0.860 (0.352 < 2.1) | 0.740 |
|
|
Cardiovascular involvement (Y/N) | 1.187 (0.839 < 1.680) | 0.334 |
|
|
Abdominal involvement (Y/N) | 1.536 (1.086 < 2.171) | 0.015 | 0.935 (0.619 < 1.413) | 0.751 |
Nervous system involvement (Y/N) | 0.934 (0.546 < 1.598) | 0.804 |
|
|
Pulmonary involvement (Y/N) | 1.432 (1.024 < 2.004) | 0.036 | 1.156 (0.718 < 1.860) | 0.551 |
ILD (Y/N) | 1.515 (1.07 < 2.145) | 0.019 | 1.042 (0.622 < 1.747) | 0.875 |
Alveolar hemorrhage (Y/N) | 1.298 (0.829 < 2.031) | 0.254 |
|
|
Kidney involvement (Y/N) | 1.728 (1.026 < 2.912) | 0.040 | 0.826 (0.453 < 1.503) | 0.531 |
SCR ≥ 500 μmol/L (vs. <500 μmol/L) | 1.935 (1.376 < 2.721) | <0.001 | 1.546 (1.075 < 2.224) | 0.019 |
C3 ≤ 0.8 g/L (vs. >0.8 g/L) | 2.554 (1.779 < 3.667) | <0.001 | 1.696 (1.148 < 2.507) | 0.008 |
Hemoglobin ≤ 90 g/L (vs. >90 g/L) | 1.998 (1.419 < 2.813) | <0.001 | 1.322 (0.893 < 1.959) | 0.163 |
ALB < 30 g/L (vs. ≥30 g/L) | 1.843 (1.316 < 2.580) | <0.001 | 1.438 (1.010 < 2.047) | 0.044 |
BVAS ≥ 15 (vs. <15) | 2.979 (2.114 < 4.197) | <0.001 | 1.943 (1.317 < 2.866) | 0.001 |
Immunosuppressive treatment (Y/N) | 0.757 (0.541 < 1.058) | 0.103 |
|
|